PHASE 3 STUDY OF SAFETY AND IMMUNOGENICITY OF GBP510 VACCINE ADJUVANTED WITH AS03 IN ADULTS
Intro: GBP510 contains the self-assembling recombinant nanoparticle displaying SARS‐CoV-2 Spike protein receptor binding domain and is adjuvanted with AS03. We report interim Phase 3 study (NCT05007951) results up to 4 weeks post-dose 2 (Data-cut: March-18-2022), where immunogenicity to the D614G an...
| Published in: | International Journal of Infectious Diseases |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-05-01
|
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971223004733 |